Novaccess Global Inc Stock Price, News & Analysis

NovAccess Global (OTC PINK:XSNX) announced that Dr. Dwain Irvin was interviewed on MoneyTV on September 11, 2021. MoneyTV, celebrating its 25th year, reaches 200 million homes across 75 countries. Dr. Irvin discussed the company's efforts to gain FDA approval for a Phase IIa Human clinical trial of an immunotherapy targeting brain tumors. NovAccess is advancing a cancer vaccine aimed at enhancing immune responses for patients with glioblastoma multiforme, a serious brain tumor with a limited survival rate.

NovAccess Global (OTC PINK:XSNX) will present at the SBMT 18th World Congress from July 8-11, 2021, in Los Angeles, a notable event focusing on advancements in neuroscience and brain mapping. Dr. Chris Wheeler, co-chairing a presentation on Brain-Immune Interactions and Inflammation on July 9, will highlight the company's progress in cancer therapeutics, particularly targeting glioblastoma multiforme. NovAccess aims to improve treatment options through innovative immunotherapeutic approaches that enhance the patient’s immune response against tumors.

NovAccess Global (OTC PINK:XSNX) received a positive response from the FDA regarding its pre-IND meeting for developing a treatment for glioblastoma multiforme (GBM). The FDA suggested an initial Phase I trial to evaluate product feasibility, toxicity, and activity, while providing guidance on compliance for future trials. They tentatively agreed that further animal studies are unnecessary and accepted the company’s enrollment plan. The global GBM market is projected to reach $1.8 billion by 2027, driven by an increasing geriatric population and the high incidence of brain cancers.

NovAccess Global (OTC PINK:XSNX) has filed its Form 10-K annual filing for FY 2020 and Form 10-Q for the first and second quarters of 2021. The company, focused on developing immunotherapies for brain tumors, is preparing for a pre-IND meeting with the FDA on June 16, 2021, to discuss starting human clinical trials. A recently approved patent protects their novel treatment approach for glioblastoma multiforme, a brain tumor with limited survival rates. CEO Dr. Dwain Irvin asserts that the company is ready to accelerate progress on its promising cancer therapeutic solutions.

NovAccess Global (OTC PINK:XSNX) has secured an unlimited use license to US Patent # 9764014, enhancing its immunotherapy technology against brain tumors. This acquisition, made in September 2020, is pivotal as it positions NovAccess to advance its treatment for glioblastoma multiforme (GBM), a brain tumor with a median survival of less than 15 months. The company plans to file an Investigational New Drug (IND) application with the FDA to initiate human clinical trials, spearheaded by Dr. Chris Wheeler, who brings over 20 years of experience in developing treatments for brain cancer.

NovAccess Global Inc. (OTC PINK:XSNX) enhances its Scientific Advisory Board by adding five distinguished experts in the fields of biotechnology and healthcare. Alongside this, they have appointed Mike Yukich as the new Chief Financial Officer, who brings over 20 years of financial expertise from both public and private sectors. The new advisory board aims to support the company's mission of advancing cancer diagnostics and therapeutics, particularly in improving immune responses in patients with brain tumors, using patented dendritic cell-based immunotherapy.

NovAccess Global (OTC PINK:XSNX) has appointed Dr. Dwain Irvin as CEO, signaling a commitment to advancing biomedical initiatives. Dr. Irvin, a seasoned cancer researcher with a PhD from UCLA, previously led the Biotechnology division at Innovest Global Inc. His extensive background includes research on neural stem cells and immunotherapy for brain tumors. This leadership change is expected to enhance the company's strategic direction and drive its commercial objectives.